Matthias H. Tschöp

Matthias H. Tschöp

Auto-generated profile, based on publicly available information

Matthias H. Tschöp

German Center for Diabetes Research (DZD), Munich, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Nature
Verified
Journal Article
Closed access
MTMatthias Tschöp
Matthias Tschöp
DSDavid L. Smiley
David L. Smiley
MHMark L. Heiman
Mark L. Heiman

3 January 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JTJoshua P. Thaler
Joshua P. Thaler
CYChun-Xia Yi
Chun-Xia Yi
ESEllen A. Schur
Ellen A. Schur
SGStephan J. Guyenet
Stephan J. Guyenet
BHBang H. Hwang
Bang H. Hwang
MSMichael W. Schwartz
Michael W. Schwartz
Rodent models of obesity induced by consuming high-fat diet (HFD) are characterized by inflammation both in peripheral tissues and in hypothalamic areas critical for energy homeostasis. Here we report that unlike inflammation in peripheral tissues, which develops as a consequence of obesity, hypothalamic inflammatory signaling was evident in both rats and mice within 1 to 3 days of HFD onset, prior to substantial weight gain. Furthermore, both reactive gliosis and markers suggestive of neuron injury were evident in the hypothalamic arcuate nucleus of rats and mice within the first week of HFD feeding. Although these responses temporarily subsided, suggesting that neuroprotective mechanisms may initially limit the damage, with continued HFD feeding, inflammation and gliosis returned permanently to the mediobasal hypothalamus. Consistent with these data in rodents, we found evidence of increased gliosis in the mediobasal hypothalamus of obese humans, as assessed by MRI. These findings collectively suggest that, in both humans and rodent models, obesity is associated with neuronal injury in a brain area crucial for body weight control.

1 April 2001 in Diabetes
Verified
Journal Article
Closed access
PDF file
MTMatthias Tschöp
Matthias Tschöp
CWChristian Weyer
Christian Weyer
PTP. Antonio Tataranni
P. Antonio Tataranni
VDViswanath Devanarayan
Viswanath Devanarayan
EREric Ravussin
Eric Ravussin
MHMark L. Heiman
Mark L. Heiman
Ghrelin is a novel endogenous natural ligand for the growth hormone (GH) secretagogue receptor that has recently been isolated from the rat stomach. Ghrelin administration stimulates GH secretion but also causes weight gain by increasing food intake and reducing fat utilization in rodents. To investigate the possible involvement of ghrelin in the pathogenesis of human obesity, we measured body composition (by dual X-ray absorption) as well as fasting plasma ghrelin concentrations (radioimmunoassay) in 15 Caucasians (8 men and 7 women, 31 ± 9 years of age, 92 ± 24 kg body wt, and 29±10% body fat, mean ± SD) and 15 Pima Indians (8 men and 7 women, 33 ± 5 years of age, 97 ± 29 kg body wt, and 30 ± 8% body fat). Fasting plasma ghrelin was negatively correlated with percent body fat (r = –0.45; P = 0.01), fasting insulin (r = – 0.45; P = 0.01) and leptin (r = –0.38; P = 0.03) concentrations. Plasma ghrelin concentration was decreased in obese Caucasians as compared with lean Caucasians (P < 0.01). Also, fasting plasma ghrelin was lower in Pima Indians, a population with a very high prevalence of obesity, compared with Caucasians (87 ± 28 vs. 129 ± 34 fmol/ml; P < 0.01). This result did not change after adjustment for fasting plasma insulin concentration. There was no correlation between fasting plasma ghrelin and height. Prospective clinical studies are now needed to establish the role of ghrelin in the pathogenesis of human obesity.

1 February 2003 in Neuron
Verified
Journal Article
Closed access
MCMichael A Cowley
Michael A Cowley
RSRoy G Smith
Roy G Smith
SDSabrina Diano
Sabrina Diano
MTMatthias Tschöp
Matthias Tschöp
NPNina Pronchuk
Nina Pronchuk
THTamas L Horvath
Tamas L Horvath

23 November 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
Timo D. MüllerTimo D. Müller
Timo D. Müller
MBMatthias Blüher
Matthias Blüher
MTMatthias H. Tschöp
Matthias H. Tschöp
RDRichard DiMarchi
Richard DiMarchi
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.

1 June 2015 in Molecular Metabolism
Verified
Journal Article
Open access
TMT.D. Müller
T.D. Müller
RNRuben Nogueiras
Ruben Nogueiras
MAM.L. Andermann
M.L. Andermann
ZAZ.B. Andrews
Z.B. Andrews
SAS.D. Anker
S.D. Anker
MTM.H. Tschöp
M.H. Tschöp
The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence supports more complicated and nuanced roles for the hormone, which go beyond the regulation of systemic energy metabolism. In this review, we discuss the diverse biological functions of ghrelin, the regulation of its secretion, and address questions that still remain 15 years after its discovery. In recent years, ghrelin has been found to have a plethora of central and peripheral actions in distinct areas including learning and memory, gut motility and gastric acid secretion, sleep/wake rhythm, reward seeking behavior, taste sensation and glucose metabolism.